Clinical trial NCT06167655: A PIVOTAL STUDY EVALUATING SAFETY AND EFFICACY OF THE SHIRATRONICS MIGRAINE THERAPY SYSTEM
Official title: A PIVOTAL STUDY EVALUATING SAFETY AND EFFICACY OF THE SHIRATRONICS MIGRAINE THERAPY SYSTEM IN RELIEVING, INTERRUPTING, AND PREVENTING CHRONIC MIGRAINE (RELIEV-CM2)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Headache Migraine Chronic
Lead sponsor: ShiraTronics
Sponsor class: INDUSTRY
First posted: 2023-12-12
Enrollment: 250
Sex: ALL
Minimum age (years): 22
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Prospective, multi-center, double blind, randomized, sham-controlled study to evaluate neuromodulation in patient with chronic migraine. The study hypothesis to be tested is the mean reduction in mean monthly headache days between patients in treatment versus sham.


Eligibility criteria: Inclusion Criteria:

1. ≥ 22 years of age.
2. Have migraine onset at ≤ 50 years of age.
3. Have a history of migraine for ≥ 12 months prior to screening.
4. Have 15 - 26 headache days/month, among which ≥ 8 days has the features of probable migraine, and minimum of 2 headache-free days/month during the 28-day screening period.
5. Fulfill the criteria for chronic migraine (CM) during the 28-day screening period.
6. Have a diagnosis of refractory chronic migraine (RCM), who have inadequate response or no access to, or are intolerant, unwilling, or contraindicated to Onabotulinum toxin A (Botox) therapy, and One of the medications that belong to Calcitonin Gene Related Peptide Monoclonal antibodies (CGRP) therapy or CGRP antagonist therapy.
7. Maintain a stable use of preventive(s) migraine medication for ≥ 3 months before screening. Subjects receiving OnabotunlinumtoxinA must stop therapy ≥ 3 months prior to screening visit.
8. Demonstrate ≥ 80% compliance with the headache diary during the screening period by entering headache data on a minimum of 22 out of 28 days.
9. Be willing and able to comply with all study procedures and return to the clinic for the follow-up evaluation, as specified in this protocol.
10. Be able to give voluntary, written informed consent to participate in this study.

Exclusion Criteria:

1. Type of headache or migraine other than RCM including the following:

   1. Post-traumatic headache (e.g., battlefield, accidents, etc.).
   2. Regular intake of opioids (including codeine) of ≥ 8 days in the past 3 months and during the 28-day screening/baseline phase and cannot be accounted for by another diagnosis.
   3. Regular intake of Barbiturates for ≥ 5 days/month in the past 3 months and during the 28-day screening/baseline phase and cannot be accounted for by another diagnosis.
   4. Report experiencing unremitting, continuous headaches with no relief.
   5. Have new daily persistent headache (NDPH) defined by iCHD-3 as persistent headache, daily from its onset, which is clearly remembered. The pain lacks characteristic features and may be migraine-like or tension-type like or have elements of both with a CM subtype.
2. History of treatments that could confound the results of the study

   1. Previously implanted neurostimulator to stimulate the greater occipital and/or supraorbital nerves to treat headache.
   2. Have received onabotulinumtoxinA (Botox) for any other medical or cosmetic reasons requiring injections in the head, face, or neck within 3 months prior to screening.
3. Have had any cervical radiofrequency ablation within 12 months.
4. Subjects with recent brain or facial trauma occurring less than 3 months prior to the Baseline Visit.
5. Subjects that may have received sequential multi-day in-patient parenteral infusion for the treatment of a migraine condition (e.g., status migrainosus) within the previous 2 weeks of the initiation of diary screening phase.
6. Subjects with any metallic implant located in the head including CSF shunt and surgical clip above the shoulder line (excluding dental implants).
7. Subject has other implanted electrical stimulation device(s) including:

   1. Cardiac pacemakers or defibrillators
   2. Cochlear implant
   3. Intrathecal pumps
   4. Spinal cord stimulator
   5. Other stimulator device
8. Use of nerve blocks, acupuncture, neurostimulation and/or transcranial magnetic stimulation) for migraine within 3 months prior to screening and after receiving implant system.
9. Any pre-existing or requirement of emergent surgery/procedure that may interfere or confound the results of the study.
10. Any known requirement for an MRI scan subsequent to implant of the neurostimulator.
11. Current or history of following comorbidities:

    1. Clinically significant psychiatric illnesses, including suicide attempt, or suicidal ideation with a specific plan in the past 2 years.
    2. Cancer in the past 5 years, except for appropriately treated nonmelanoma skin carcinoma.
    3. Have a current diagnosis or condition that presents excess risk for performing the procedure, as determined clinically by the Investigator.
    4. Substance use disorder of at least moderate severe for substances such as; alcohol, recreational marijuana, or illicit drugs during the past 2 years.
12. Unable to participate or successfully complete the study, in the opinion of the investigator.
13. Anatomy not suitable for placement of the study device.
14. Are currently a study center or Sponsor employee who is directly involved in the study or the relative of such an employee.
15. Pregnant or lactating female or planning a pregnancy during participation in the study.
16. Patient with life expectancy of less than 1.5 years.
17. Currently participating in or planning to participate in other investigational drug or device studies that may interfere or confound the results of the study.

Primary outcomes:
measure: Headache Days
timeFrame: 12-weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Mayo Clinic Arizona
state: Arizona
city: Little Rock
country: United States
facility: University of Arkansas for Medical Sciences
state: Arkansas
city: La Jolla
country: United States
facility: UC San Diego Health
state: California
city: Napa
country: United States
facility: Neurovations
state: California
city: Denver
country: United States
facility: Barolat Neuroscience
state: Colorado
city: Hartford
country: United States
facility: Ayer Neuroscience Institute Headache Center
state: Connecticut
city: Jacksonville
country: United States
facility: Mayo Clinic Florida
state: Florida
city: Newnan
country: United States
facility: Vista Clinical Research and Summit Spine & Joint
state: Georgia
city: Chaska
country: United States
facility: iSpine Clinics
state: Minnesota
city: Rochester
country: United States
facility: Mayo Clinic Rochester
state: Minnesota
city: Amherst
country: United States
facility: Dent Neurologic Institute
state: New York
city: New York
country: United States
facility: Northwell Health Physician Partners
state: New York
city: Charlotte
country: United States
facility: Queen City Clinical Research
state: North Carolina
city: Winston-Salem
country: United States
facility: The Center for Clinical Research
state: North Carolina
city: Lancaster
country: United States
facility: Argires Marotti Neurological Associates
state: Pennsylvania
city: Philadelphia
country: United States
facility: Jefferson Headache Center
state: Pennsylvania
city: Dallas
country: United States
facility: Texas Neurology
state: Texas
city: Broadmeadow
country: Australia
facility: Genesis Research Services
state: New South Wales
city: Wayville
country: Australia
facility: CerCare
state: South Australia
city: Melbourne
country: Australia
facility: Monash House Research Centre
state: Victoria
Study officials:
affiliation: Hartford Headache Center
name: Brian Grosberg, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University Hospitals
name: Samer Narouze, MD
role: PRINCIPAL_INVESTIGATOR
References: